UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Linc00941 fuels ribogenesis and protein synthesis by supporting robust cMYC translation in malignant pleural mesothelioma

Cancer letters, 2024-06, Vol.592, p.216950, Article 216950

2024

Volltextzugriff (PDF)

Mesothelioma-associated fibroblasts enhance proliferation and migration of pleural mesothelioma cells via c-Met/PI3K and WNT signaling but do not protect against cisplatin

Journal of experimental & clinical cancer research, 2023-01, Vol.42 (1), p.27-27, Article 27

2023

Volltextzugriff (PDF)

Exploiting the folate receptor α in oncology

Nature reviews. Clinical oncology, 2020-06, Vol.17 (6), p.349-359

2020

Volltextzugriff (PDF)

Tumor Suppressor microRNAs Contribute to the Regulation of PD-L1 Expression in Malignant Pleural Mesothelioma

Journal of thoracic oncology, 2017-09, Vol.12 (9), p.1421-1433

2017

Volltextzugriff (PDF)

Analysis of expression of programmed cell death 1 ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM)

PloS one, 2015-03, Vol.10 (3), p.e0121071-e0121071

2015

Volltextzugriff (PDF)

Novel therapies for malignant pleural mesothelioma

The lancet oncology, 2018-03, Vol.19 (3), p.e161-e172

2018

Volltextzugriff (PDF)

Immunohistochemical detection of MTAP and BAP1 protein loss for mesothelioma diagnosis: Comparison with 9p21 FISH and BAP1 immunohistochemistry

Lung cancer (Amsterdam, Netherlands), 2017-02, Vol.104, p.98-105

2017

Volltextzugriff (PDF)

A combination of MTAP and BAP1 immunohistochemistry is effective for distinguishing sarcomatoid mesothelioma from fibrous pleuritis

Lung cancer (Amsterdam, Netherlands), 2018-11, Vol.125, p.198-204

2018

Volltextzugriff (PDF)

Restoring expression of miR-16: a novel approach to therapy for malignant pleural mesothelioma

Annals of oncology, 2013-12, Vol.24 (12), p.3128-3135

2013

Volltextzugriff (PDF)

Multifactorial T-cell Hypofunction That Is Reversible Can Limit the Efficacy of Chimeric Antigen Receptor―Transduced Human T cells in Solid Tumors

Clinical cancer research, 2014-08, Vol.20 (16), p.4262-4273

2014

Volltextzugriff (PDF)

Maintenance Defactinib Versus Placebo After First-Line Chemotherapy in Patients With Merlin-Stratified Pleural Mesothelioma: COMMAND-A Double-Blind, Randomized, Phase II Study

Journal of clinical oncology, 2019-04, Vol.37 (10), p.790-798

2019

Volltextzugriff (PDF)

Novel insights into mesothelioma biology and implications for therapy

Nature reviews. Cancer, 2017-08, Vol.17 (8), p.475-488

2017

Volltextzugriff (PDF)

The Immune Microenvironment, Genome-wide Copy Number Aberrations, and Survival in Mesothelioma

Journal of thoracic oncology, 2017-05, Vol.12 (5), p.850-859

2017

Volltextzugriff (PDF)

Statin suppresses Hippo pathway-inactivated malignant mesothelioma cells and blocks the YAP/CD44 growth stimulatory axis

Cancer letters, 2017-01, Vol.385, p.215-224

2017

Volltextzugriff (PDF)

Expression of a Functional CCR2 Receptor Enhances Tumor Localization and Tumor Eradication by Retargeted Human T cells Expressing a Mesothelin-Specific Chimeric Antibody Receptor

Clinical cancer research, 2011-07, Vol.17 (14), p.4719-4730

2011

Volltextzugriff (PDF)

Mesothelin-Targeted Thorium-227 Conjugate (MSLN-TTC): Preclinical Evaluation of a New Targeted Alpha Therapy for Mesothelin-Positive Cancers

Clinical cancer research, 2019-08, Vol.25 (15), p.4723-4734

2019

Volltextzugriff (PDF)

Intracavitary ‘T4 immunotherapy’ of malignant mesothelioma using pan-ErbB re-targeted CAR T-cells

Cancer letters, 2017-05, Vol.393, p.52-59

2017

Volltextzugriff (PDF)

Exosomal transfer of miR-126 promotes the anti-tumour response in malignant mesothelioma: Role of miR-126 in cancer-stroma communication

Cancer letters, 2019-10, Vol.463, p.27-36

2019

Volltextzugriff (PDF)

Targeted Next-Generation Sequencing of Cancer Genes in Advanced Stage Malignant Pleural Mesothelioma: A Retrospective Study

Journal of thoracic oncology, 2015-03, Vol.10 (3), p.492-499

2015

Volltextzugriff (PDF)

Metabolic rewiring and redox alterations in malignant pleural mesothelioma

British journal of cancer, 2020-01, Vol.122 (1), p.52-61

2020

Volltextzugriff (PDF)

BAP1 Is Altered by Copy Number Loss, Mutation, and/or Loss of Protein Expression in More Than 70% of Malignant Peritoneal Mesotheliomas

Journal of thoracic oncology, 2017-04, Vol.12 (4), p.724-733

2017

Volltextzugriff (PDF)

Germline Mutation of Bap1 Accelerates Development of Asbestos-Induced Malignant Mesothelioma

Cancer research (Chicago, Ill.), 2014-08, Vol.74 (16), p.4388-4397

2014

Volltextzugriff (PDF)

A phase 1b clinical trial of the CD40-activating antibody CP-870,893 in combination with cisplatin and pemetrexed in malignant pleural mesothelioma

Annals of oncology, 2015-12, Vol.26 (12), p.2483-2490

2015

Volltextzugriff (PDF)

Wnt/IL‐1β/IL‐8 autocrine circuitries control chemoresistance in mesothelioma initiating cells by inducing ABCB5

International journal of cancer, 2020-01, Vol.146 (1), p.192-207

2020

Volltextzugriff (PDF)

Gemcitabine Synergizes with Immune Checkpoint Inhibitors and Overcomes Resistance in a Preclinical Model and Mesothelioma Patients

Clinical cancer research, 2018-12, Vol.24 (24), p.6345-6354

2018

Volltextzugriff (PDF)

1 – 25 von 1.147

Suche als RSS-Feed

Aktive Filter

SpracheJapanisch

ThemaOncology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(1.038)
Mit Volltextzugriff
(1.074)

Publikationsform

Sprache

Englisch
(1.146)
Deutsch
(1)

Erscheinungsjahr

n.n

Thema

14 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Linc00941 fuels ribogenesis and protein synthesis by supporting robust cMYC translation in malignant pleural mesothelioma

Mesothelioma-associated fibroblasts enhance proliferation and migration of pleural mesothelioma cells via c-Met/PI3K and WNT signaling but do not protect against cisplatin

Exploiting the folate receptor α in oncology

Tumor Suppressor microRNAs Contribute to the Regulation of PD-L1 Expression in Malignant Pleural Mesothelioma

Analysis of expression of programmed cell death 1 ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM)

Novel therapies for malignant pleural mesothelioma

Immunohistochemical detection of MTAP and BAP1 protein loss for mesothelioma diagnosis: Comparison with 9p21 FISH and BAP1 immunohistochemistry

A combination of MTAP and BAP1 immunohistochemistry is effective for distinguishing sarcomatoid mesothelioma from fibrous pleuritis

Restoring expression of miR-16: a novel approach to therapy for malignant pleural mesothelioma

Multifactorial T-cell Hypofunction That Is Reversible Can Limit the Efficacy of Chimeric Antigen Receptor―Transduced Human T cells in Solid Tumors

Maintenance Defactinib Versus Placebo After First-Line Chemotherapy in Patients With Merlin-Stratified Pleural Mesothelioma: COMMAND-A Double-Blind, Randomized, Phase II Study

Novel insights into mesothelioma biology and implications for therapy

The Immune Microenvironment, Genome-wide Copy Number Aberrations, and Survival in Mesothelioma

Statin suppresses Hippo pathway-inactivated malignant mesothelioma cells and blocks the YAP/CD44 growth stimulatory axis

Expression of a Functional CCR2 Receptor Enhances Tumor Localization and Tumor Eradication by Retargeted Human T cells Expressing a Mesothelin-Specific Chimeric Antibody Receptor

Mesothelin-Targeted Thorium-227 Conjugate (MSLN-TTC): Preclinical Evaluation of a New Targeted Alpha Therapy for Mesothelin-Positive Cancers

Intracavitary ‘T4 immunotherapy’ of malignant mesothelioma using pan-ErbB re-targeted CAR T-cells

Exosomal transfer of miR-126 promotes the anti-tumour response in malignant mesothelioma: Role of miR-126 in cancer-stroma communication

Targeted Next-Generation Sequencing of Cancer Genes in Advanced Stage Malignant Pleural Mesothelioma: A Retrospective Study

Metabolic rewiring and redox alterations in malignant pleural mesothelioma

BAP1 Is Altered by Copy Number Loss, Mutation, and/or Loss of Protein Expression in More Than 70% of Malignant Peritoneal Mesotheliomas

Germline Mutation of Bap1 Accelerates Development of Asbestos-Induced Malignant Mesothelioma

A phase 1b clinical trial of the CD40-activating antibody CP-870,893 in combination with cisplatin and pemetrexed in malignant pleural mesothelioma

Wnt/IL‐1β/IL‐8 autocrine circuitries control chemoresistance in mesothelioma initiating cells by inducing ABCB5

Gemcitabine Synergizes with Immune Checkpoint Inhibitors and Overcomes Resistance in a Preclinical Model and Mesothelioma Patients

Aktive Filter

Suchergebnisse filtern